| DB ID | MyCo_2364 |
| Title | Comparative performance of Aspergillus galactomannan ELISA and PCR in sputum from patients with ABPA and CPA |
| Year | 2017 |
| PMID | 28645480 |
| Fungal Diseases involved | Allergic bronchopulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The audit was registered with the University Hospital of South Manchester audit department. |
| Site of Infection | Lungs |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | UK |
| Cohort | ABPA or CPA demographic patient data were retrieved. This retrospective observational audit included 159 patients with at least one sputum pair. 223 sputum sample pairs were analysed, as well as six control samples for GM only. Real time PCR was performed following sputum DNA extraction using the MycAssayTM Aspergillus kit and cycle thresholds were subtracted from 38 to give positive values (transformed Ct, TCt). |
| Cohort No. | 159 Patients |
| Age Group | 29-100 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Aspergillus species may cause life-threatening respiratory infections including invasive pulmonary aspergillosis, and allergic and chronic lung disease. A small number of species of Aspergillus are responsible for pulmonary aspergillosis including allergic bronchopulmonary aspergillosis (ABPA) and chronic pulmonary aspergillosis (CPA). While ABPA is a noninvasive form of Aspergillus lung disease with hypersensitivity manifestations in patients who have pre-existing atopy, asthma or cystic fibrosis, CPA manifests in patients who have impaired immunity and chronic obstructive pulmonary diseases (COPD). Globally, about 6.8% of asthmatic patients and those with corticosteroid-complicated asthma develop ABPA. Among cystic fibrosis patients, the prevalence of ABPA was found to be 2-15%, increasing to 18 % among children. The global burden of CPA complicating ABPA has been estimated to be approximately 400,000 patients. Most subjects with a simple aspergilloma are asymptomatic except for haemoptysis which occurs in about 50-90% of cases. Confirmation of diagnosis of these infections requires assessment of clinical symptoms, positive Aspergillus spp. culture from respiratory secretions, histological demonstration of fungal invasion, detection of Aspergillus IgG antibody and other immunological tests as well as review of radiological appearances. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA Kit MycAssay® Aspergillus (Lab21, Cambridge, UK). |
| Assay Data | None |
| Validation Techniques used | ELISA, RT-PCR |
| Up Regulation Down Regulation | Not Cleared |
| Sequence Data | None |
| External Link | None |
